Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders

June 27, 2011 By Bio-Medicine.Org

SEATTLE, June 27, 2011 /PRNewswire/ — Omeros Corporation
(NASDAQ:
OMER
) today reported that it has identified compounds that
interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and
OPN4. P2Y8 (also known as P2RY8) is associated with acute
lymphoblastic leukemia (ALL), an aggressive cancer of the white
blood cells. ALL is the most common type of malignancy diagnosed in
children. The OPN4 receptor is involved with regulation of
circadian rhythms, and could provide a target for drugs to improve
alertness and to treat a wide range of sleep disorders ranging from
narcolepsy and jet lag to insomnia.

Omeros has now announced that it has unlocked 10 of the 81 Class
A orphan GPCRs. GPCRs represent the premier family of drug targets,
with more than 30 percent of currently marketed drugs targeting
only 46 GPCRs. There are approximately 120 orphan GPCRs, and
Omeros, which expects to unlock a large percentage of these for
drug development, is initially targeting Class A orphan GPCRs.

“The P2Y8 and OPN4 receptors are linked to important therapeutic
areas that receive significant industry attention,” said Gregory A.
Demopulos, M.D., chairman and chief executive officer of Omeros.
“By identifying compounds that interact with these two orphan
receptors, our proprietary screening technology has opened
previously closed drug-development pathways for ALL and sleep
disorders.”

Ongoing GPCR Program

Omeros has begun screening orphan GPCRs against its
small-molecule chemical libraries using its proprietary,
high-throughput cellular redistribution assay (CRA). Omeros has
announced that it has identified and confirmed sets of compounds
that interact selectively with 10 orphan receptors linked to
squamous cell carcinoma (GPR87), pancreatic cancer (GPR182),acute
lymphoblastic leukemia (P2Y8/P2RY8), metabolic and psychotic
disorders(GPR27, GPR85, GPR173), appetite c

‘/>”/>

SOURCE

Related Articles Read More >

Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech